New EASL clinical practice guidelines on the management of hepatitis B virus

April 20, 2017
Electron micrograph of hepatitis B virus. Credit: Centers for Disease Control and Prevention

The European Association for the Study of the Liver (EASL) today published their revised Clinical Practice Guidelines (CPGs) on the management of Hepatitis B virus (HBV) infection. The CPGs, which will also be presented in a session at The International Liver Congress 2017 in Amsterdam, The Netherlands, are designed to help physicians and healthcare providers optimise the management of patients with either acute or chronic HBV.

The new EASL HBV CPGs are the first international guidelines to include the new antiviral drug tenofovir alafenamide (TAF), as well as the latest scientific evidence on stopping antiviral therapy in distinct patient populations on long-term treatment.

HBV infection remains a global public health burden with changing epidemiology due to several factors including vaccination policies and migration. All patients with chronic HBV are at increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC), depending on host and viral factors. The main goal of therapy is to improve survival and quality of life by preventing disease progression, and consequently HCC development. The induction of long-term suppression of HBV replication represents the main endpoint of current treatment strategies, while loss of HBsAg (a surface antigen of HBV which indicates current infection) is an optimal endpoint.

"Hepatitis B virus infections are major health threats that affect about 240 million individuals worldwide. The updated EASL guidelines integrate the latest scientific advances on diagnosis and therapy of Hepatitis B, thereby providing clear guidance to clinicians and patients for the management of this potentially life-threatening disease," said Prof Frank Tacke, member of the Clinical Practice Guideline panel and EASL Governing Board Member.

Based on an extensive systematic review of the most current literature by a panel of leading global experts, the updated HBV CPGs provide:

  • New definitions of disease phases that will better guide clinicians on treatment indications
  • Expanded indications for initiating treatment in order to prevent mother-to-child transmission, based on the latest scientific evidence
  • Clear cut recommendations for special patient populations (e.g., children, extrahepatic disease manifestations, prevention of HBV re-activation)
  • Practical rules for response-guided therapy in receiving pegylated interferon for HBV

The guidelines will be published in the official journal of EASL, the Journal of Hepatology (Vol. 67 Issue. 2, August 2017) and presented during a session at The International Liver CongressTM 2017 on Thursday, 20 April 2017, from 12:30 - 13:15, in Hall 5.

Explore further: European countries restrict access to life-saving treatment for hepatitis C

Related Stories

European countries restrict access to life-saving treatment for hepatitis C

April 20, 2017
Data presented today demonstrate that there are considerable restrictions in the reimbursement of direct-acting antiviral (DAA) therapy across European countries, particularly with respect to the severity of liver fibrosis ...

New clinical practice guidelines on alcoholic liver disease published

April 19, 2012
EASL today announced the publication of a new clinical practice guideline (CPG) in the area of Alcoholic Liver Disease (ALD), bringing the number of CPGs published to date to eight.

EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus

December 9, 2013
The European Association for the Study of the Liver (EASL) today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection (HCV) (1). The EASL guidelines, which supersede ...

EASL publishes online recommendations on the management of hepatitis C

April 9, 2014
The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress (ILC). These EASL recommendations ...

Study demonstrates benefits of existing treatment for hepatitis D patients

April 15, 2016
New research presented today shows that interferon alpha (IFNa) based therapies are effective in suppressing disease progression in a severe form of chronic viral hepatitis, Hepatitis delta.

EASL-EORTC publish joint clinical practice guidelines on hepatocellular carcinoma management

March 15, 2012
The European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) today publish their first joint Clinical Practice Guidelines (CPGs) on the management of ...

Recommended for you

Four simple tests could help GPs spot pneumonia and reduce unnecessary antibiotics

November 23, 2017
Testing for fever, high pulse rate, crackly breath sounds, and low oxygen levels could be key to helping GPs distinguish pneumonia from less serious infections, according to a large study published in the European Respiratory ...

New approach to tracking how deadly 'superbugs' travel could slow their spread

November 22, 2017
Killer bacteria - ones that have out-evolved our best antibiotics—may not go away anytime soon. But a new approach to tracking their spread could eventually give us a fighting chance to keep their death toll down.

Research points to diagnostic test for top cause of liver transplant in kids

November 22, 2017
Biliary atresia is the most common cause of liver transplants for children in the United States. Now researchers report in Science Translational Medicine finding a strong biomarker candidate that could be used for earlier ...

Metabolites altered in chronic kidney disease

November 22, 2017
Chronic kidney disease (CKD) affects 1 in 7 people in the United States, according to the U.S. National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK). These individuals have a very high risk of cardiovascular ...

Rainfall can indicate that mosquito-borne epidemics will occur weeks later

November 22, 2017
A new study demonstrates that outbreaks of mosquito-borne viruses Zika and Chikungunya generally occur about three weeks after heavy rainfall.Researchers also found that Chikungunya will predominate over Zika when both circulate ...

Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

November 22, 2017
A new study provides insights into the interaction between alcohol consumption and metabolic factors in predicting severe liver disease in the general population. The findings, which are published in Hepatology, indicate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.